Abstract: A system and method are provided for personalized browsing using a remote device on an electronic device. A page associated with at least one user is display and one or more navigable elements on the displayed page are identified. One or more categories of the one or more navigable elements are created and the one or more navigable elements are classified based on at least one category of the one or more categories. Hybrid blocks are generated based on a category of the one or more navigable elements and user profile data and a content similarity check between the hybrid blocks is performed. A relevance matrix is created based on pre-defined context parameters and the content similarity check. An element of interest is navigated to based on the relevance matrix and the hybrid block.

Abstract: A method for personalized browsing by using a remote device, includes: displaying a page associated with at least one user; identifying one or more navigable elements on the displayed page; creating one or more categories of the one or more navigable elements; classifying the one or more navigable elements based on at least one category of the one or more categories; generating hybrid blocks based on a category of the one or more navigable elements and user profile data; performing a content similarity check between the hybrid blocks; creating a relevance matrix based on pre-defined context parameters and the content similarity check; and navigating to an element of interest based on the relevance matrix and the hybrid block.

Abstract: A method to adaptively predict non-default actions against unstructured utterances by an automated assistant operating in a computing-system is provided. The method includes extracting voice-features based on receiving an input utterance from at-least one speaker by an automatic speech recognition (ASR) device, identifying the input utterance as an unstructured utterance based on the extracted voice-features and a mapping between the input utterance with one or more default actions as drawn by the ASR, obtaining at least one probable action to be performed in response to the unstructured utterance through a dynamic bayesian network (DBN). The method further includes providing the at least one probable action obtained by the DBN to the speaker in an order of the posterior probability with respect to each action.

Abstract: A method to adaptively predict non-default actions against unstructured utterances by an automated assistant operating in a computing-system is provided. The method includes extracting voice-features based on receiving an input utterance from at-least one speaker by an automatic speech recognition (ASR) device, identifying the input utterance as an unstructured utterance based on the extracted voice-features and a mapping between the input utterance with one or more default actions as drawn by the ASR, obtaining at least one probable action to be performed in response to the unstructured utterance through a dynamic bayesian network (DBN). The method further includes providing the at least one probable action obtained by the DBN to the speaker in an order of the posterior probability with respect to each action.

Abstract: A pharmaceutically acceptable composition and method of therapy for a kinase-dependent malignancy in a patient in need of such therapy is provided. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for kinase-dependent malignancy. Also provided is a method to eradicate leukemia initiating cells (LIC) or cancer stem cells (CSC) in a patient being treated with a tyrosine kinase inhibitor.

Abstract: Methods and compositions disclosed herein generally relate to methods, compounds, and compositions for treating myeloproliferative neoplasms (MPNs) or a symptom thereof, comprising administering, to a subject in need thereof, a therapeutically effective amount of a DUSP1 inhibiting compound, or of a pharmaceutically acceptable salt, ester, solvate, pharmaceutically usable derivative, or prodrug thereof. Embodiments of the invention also relate to use of a compound, or pharmaceutically acceptable salt, ester, solvate, pharmaceutically usable derivative, or prodrug thereof, for the preparation of a composition or medicament for the treatment of a myeloproliferative neoplasm (MPN), wherein the compound is an inhibitor of DUSP1.

Abstract: A pharmaceutically acceptable composition and method of therapy for a kinase-dependent malignancy in a patient in need of such therapy is provided. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for kinase-dependent malignancy. Also provided is a method to eradicate leukemia initiating cells (LIC) or cancer stem cells (CSC) in a patient being treated with a tyrosine kinase inhibitor.

Abstract: A pharmaceutically acceptable composition and method of therapy for a kinase-dependent malignancy in a patient in need of such therapy is provided. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for kinase-dependent malignancy. Also provided is a method to eradicate leukemia initiating cells (LIC) or cancer stem cells (CSC) in a patient being treated with a tyrosine kinase inhibitor.

Abstract: The anti-inflammatory zinc(II) complex, viz., crystalline bis(chloro)-(N,N?-(2,2-dimethylpropane-1,3-diyl)bis(1-(2-chlorophenyl)-methanimine))-zinc zinc(II) complex, may be used as an anti-inflammatory. The compound has the formula: This complex is prepared by reaction of a Schiff base, namely, N,N?-bis(2-chlorobenzylidene)-2,2-dimethylpropane-1,3-diamine, with zinc chloride in alcohol to form a precipitate, which is removed by filtration, followed by slow evaporation of the filtrate to obtain the crystalline product. In vivo testing showed that the above zinc(II) complex exhibited good anti-inflammatory effect. It is thought that the present zinc-based anti-inflammatory avoids the gastrointestinal side effects of conventional NSAIDs due to the coordinated zinc complex.

Abstract: Methods and compositions disclosed herein generally relate to methods, compounds, and compositions for treating myeloproliferative neoplasms (MPNs) or a symptom thereof, comprising administering, to a subject in need thereof, a therapeutically effective amount of a DUSP1 inhibiting compound, or of a pharmaceutically acceptable salt, ester, solvate, pharmaceutically usable derivative, or prodrug thereof. Embodiments of the invention also relate to use of a compound, or pharmaceutically acceptable salt, ester, solvate, pharmaceutically usable derivative, or prodrug thereof, for the preparation of a composition or medicament for the treatment of a myeloproliferative neoplasm (MPN), wherein the compound is an inhibitor of DUSP1.

Abstract: A pharmaceutically acceptable composition and method for leukemia therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of BCR-ABL tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for leukemia.

Abstract: A pharmaceutically acceptable composition and method for leukemia therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of BCR-ABL tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for leukemia.

Abstract: A pharmaceutically acceptable composition and method for solid tumor therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, and (b) an inhibitor of Dusp-1, and optionally (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for solid tumors.

Abstract: A pharmaceutically acceptable composition and method for leukemia therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of BCR-ABL tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for leukemia.

Abstract: The present invention is directed to methods to determine the likelihood of therapeutic effectiveness of a farnesyl transferase inhibitor (FTI). The method comprises determining whether the gene encoding the farnesyl transferase beta subunit (FNTB) of said patient comprises at least one nucleic acid variance that causes an alteration in an amino acid residue. The change in the amino acid residue is associated with resistance to a FTI. The absence of at least one variance indicates that the FTI is likely to be effective.